Head-to-head evidence
Diazepam (Valium) vs Staccato Alprazolam
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Diazepam (Valium)
Marketed by Roche
NCT03428360 · Phase 3 · completed
This was a single-group, open-label study with no randomization, blinding, or comparator arm; 149 participants were enrolled and 130 received study drug. Its primary safety outcomes were descriptive and had no formal between-group comparison, so the findings provide limited evidence for assessing diazepam buccal film.
Staccato Alprazolam
Developed by UCB
NCT03478982 · Phase 2 · completed
The study randomized participants to Staccato alprazolam or matching placebo and was described as quadruple-blind, with 156 participants enrolled and 38, 38, and 40 participants in the evaluable 1.0-mg, 2.0-mg, and placebo groups, respectively. Its primary clinical endpoint—seizure cessation within 2 minutes without recurrence for 2 hours—was statistically significantly better with both alprazolam doses than with placebo.
Next expected readout: October 2026 · NCT05077904 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diazepam (Valium)'s landscape · Staccato Alprazolam's landscape